172 related articles for article (PubMed ID: 37205010)
21. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
Engelman JA; Jänne PA; Mermel C; Pearlberg J; Mukohara T; Fleet C; Cichowski K; Johnson BE; Cantley LC
Proc Natl Acad Sci U S A; 2005 Mar; 102(10):3788-93. PubMed ID: 15731348
[TBL] [Abstract][Full Text] [Related]
22. Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating PI3K/AKT signalling pathway.
Liu X; Jiang T; Li X; Zhao C; Li J; Zhou F; Zhang L; Zhao S; Jia Y; Shi J; Gao G; Li W; Zhao J; Chen X; Su C; Ren S; Zhou C
J Cell Mol Med; 2020 Jan; 24(2):1529-1540. PubMed ID: 31894895
[TBL] [Abstract][Full Text] [Related]
23. Combined treatment with N-acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line.
Li J; Wang XH; Hu J; Shi M; Zhang L; Chen H
Cancer Med; 2020 Feb; 9(4):1495-1502. PubMed ID: 31891230
[TBL] [Abstract][Full Text] [Related]
24. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
[TBL] [Abstract][Full Text] [Related]
25. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
[TBL] [Abstract][Full Text] [Related]
26. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
27. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
[TBL] [Abstract][Full Text] [Related]
28. Krüppel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer.
Feng W; Xie Q; Liu S; Ji Y; Li C; Wang C; Jin L
Cancer Sci; 2018 Jun; 109(6):1775-1786. PubMed ID: 29624806
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.
Van Schaeybroeck S; Kyula J; Kelly DM; Karaiskou-McCaul A; Stokesberry SA; Van Cutsem E; Longley DB; Johnston PG
Mol Cancer Ther; 2006 May; 5(5):1154-65. PubMed ID: 16731747
[TBL] [Abstract][Full Text] [Related]
30. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M
Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974
[TBL] [Abstract][Full Text] [Related]
31. Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.
La Monica S; Caffarra C; Saccani F; Galvani E; Galetti M; Fumarola C; Bonelli M; Cavazzoni A; Cretella D; Sirangelo R; Gatti R; Tiseo M; Ardizzoni A; Giovannetti E; Petronini PG; Alfieri RR
PLoS One; 2013; 8(10):e78656. PubMed ID: 24167634
[TBL] [Abstract][Full Text] [Related]
32. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
33. [Cigarette Smoke Induces Gefitinib Resistance in NSCLC Cells
via ROS/Sirt3/SOD2 Pathway].
Zi Y; Liao K; Chen H
Zhongguo Fei Ai Za Zhi; 2023 Apr; 26(4):245-256. PubMed ID: 37183639
[TBL] [Abstract][Full Text] [Related]
34. An effective drug sensitizing agent increases gefitinib treatment by down regulating PI3K/Akt/mTOR pathway and up regulating autophagy in non-small cell lung cancer.
Zhang J; Qu Z; Yao H; Sun L; Harata-Lee Y; Cui J; Aung TN; Liu X; You R; Wang W; Hai L; Adelson DL; Lin L
Biomed Pharmacother; 2019 Oct; 118():109169. PubMed ID: 31310954
[TBL] [Abstract][Full Text] [Related]
35. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
[TBL] [Abstract][Full Text] [Related]
36. Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells.
Tian Y; Zhang Z; Miao L; Yang Z; Yang J; Wang Y; Qian D; Cai H; Wang Y
Oncol Res; 2016; 24(5):295-303. PubMed ID: 27712586
[TBL] [Abstract][Full Text] [Related]
37. RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer.
Kaneto N; Yokoyama S; Hayakawa Y; Kato S; Sakurai H; Saiki I
Cancer Sci; 2014 Jul; 105(7):788-94. PubMed ID: 24750242
[TBL] [Abstract][Full Text] [Related]
38. Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Zhu X; Jiang H; Li J; Xu J; Fei Z
Med Sci Monit; 2016 Apr; 22():1435-41. PubMed ID: 27125283
[TBL] [Abstract][Full Text] [Related]
39. MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines.
Zhou YM; Liu J; Sun W
Asian Pac J Cancer Prev; 2014; 15(3):1391-6. PubMed ID: 24606471
[TBL] [Abstract][Full Text] [Related]
40. TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway.
Xiao Z; Li M; Zhang X; Rong X; Xu H
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36896765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]